XORTX Therapeutics (XRTX) Cash & Equivalents (2020 - 2026)

XORTX Therapeutics (XRTX) has 7 years of Cash & Equivalents data on file, last reported at $250275.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 86.79% year-over-year to $250275.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $250275.0 (down 86.79% YoY) and the FY2025 annual result came in at $864514.0, down 65.05% from the prior year.
• Cash & Equivalents eased to $250275.0 in Q1 2026, from $864514.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $12.2 million in Q1 2022 to a low of $250275.0 in Q1 2026.
• A 5-year average of $4.8 million and a median of $3.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 134.84% — and 2026, when it slumped 86.79%.
• Tracing XRTX's Cash & Equivalents over 5 years: stood at $10.4 million in 2022, then plunged by 66.87% to $3.4 million in 2023, then dropped by 28.25% to $2.5 million in 2024, then slumped by 65.05% to $864514.0 in 2025, then plunged by 71.05% to $250275.0 in 2026.
• The last three Cash & Equivalents figures came in at $250275.0 (Q1 2026), $864514.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.